arrow
A

Andrea Mega

bolzano regional hospital
H指数:19
被引数:1,402

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Updating the Prevalence of H. pylori and Extensive Precancerous Lesions in the Stomach: Results of a Multicenter, Endoscopic Study

更新幽门螺杆菌感染及胃内广泛癌前病变的患病率:一项多中心内镜研究的结果

2026-09-190
OA
Age threshold and symptoms are useful for scheduling upper endoscopy in clinical practice

年龄阈值和症状对于临床实践中上消化道内镜检查的安排具有实用价值

2026-08-180
PRE
Outcome of hepatic resection for HCC in ideal and non-ideal candidates

理想和非理想候选者行肝切除治疗HCC的结局

2025-07-290
OA
Outcome of hepatic resection for hepatocellular carcinoma in ideal and non-ideal candidates
2025-02-010
PRE
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma

丙型肝炎病毒复制缺失与抗HCV阳性肝细胞癌患者预后改善相关

2025-01-080
OAAI
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis

非侵入性评估原发性胆汁性胆管病患者的门静脉高压受胆汁淤积严重程度的影响

2024-12-130
OAAI
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

索拉非尼和节律性卡培他滨在Child-Pugh B级晚期肝癌患者中的应用: 与最佳支持治疗的现实比较

2024-09-014
PRE
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma
2024-03-012
OAAI
Physical activity in liver transplant recipients: a large multicenter study

肝移植受者的身体活动: 一项大型多中心研究

2023-11-207
OAAI
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection

一线肝切除术治疗的肝细胞癌患者不可移植复发的预测因素

2023-09-277
OAAI
Predictors of extrahepatic progression in patients with hepatocellular carcinoma receiving transarterial chemoembolization
2023-09-010
PRE
Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care
2023-09-010
PRE
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
2023-08-016
OAAI
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors
2022-11-0113
PRE